A global ayahuasca survey has found 70% experience physical and 55% mental health adverse effects, but only 2.3% of participants reporting physical adverse events required medical...
Tryp has announced interim data for the first five patients dosed in its Phase 2 trial, stating the data supports the potential effectiveness of psilocybin-assisted psychotherapy...
The nonprofit Multidisciplinary Association for Psychedelic Studies’ (MAPS) has announced its clinical research programme has had a successful confirmatory Phase 3 trial of MDMA-assisted therapy for...
Tryp Therapeutics and MGH will fund and conduct a Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients suffering from...
Algernon Pharmaceuticals (AGN Pharma) has established Algernon NeuroScience (AGN Neuro), a new wholly-owned private subsidiary of AGN Pharma, to advance its DMT stroke programme.
A new study, led by University of California – Riverside (UCR) doctoral ethnomusicology student Owain J.
In this article, Evan Lewis, director of the Neurology Centre of Toronto, VP Psychedelic Neurology for Numinus and an expert in cannabis and childhood epilepsy, discusses...
With psychedelics and psychedelic-assisted psychotherapy showing promise as potential treatments for mental health conditions, skilled facilitators who can provide therapy for patients and in clinical trials...
Beckley Psytech has announced a new clinical trial investigating its novel formulation of the psychedelic drug DMT for the treatment of depression.
The Psychedelics as Medicine Report has revealed the industry is currently worth US$650 million (~£542 million), and is expected to exceed US$3 billion by 2026.